Elörehaladott stádiumú Hodgkin-kóros betegek kezelése CCNU, etoposide és prednimustine (CEP) terápiával.

Translated title of the contribution: Treatment of advanced stage Hodgkin disease with CCNU, etoposide and prednimustine (CEP)

A. Illés, A. Bányai, G. Szegedi

Research output: Contribution to journalArticle

Abstract

The authors treated 21 advanced, pretreated Hodgkin's disease patients with CEP (CCNU, etoposide, prednimustine) polychemotherapy between March 1988 and February 1993. Complete remission was achieved in 4 patients, partial remission in 8 patients, while 9 patients were unresponsive to treatment. None of the complete responders relapsed during the follow-up period, and the median duration of remission was 24 months. The median survival for the unresponsive and partially responsive patients was less than half a year. Side-effects included gastrointestinal symptoms, myelosuppression and alopecia, but treatment-related deaths did not occur. The present data confirm the favourable impact of CEP polychemotherapy on pretreated, advanced Hodgkin's disease patients.

Original languageHungarian
Pages (from-to)1187-1190
Number of pages4
JournalOrvosi Hetilap
Volume135
Issue number22
Publication statusPublished - May 29 1994

Fingerprint

Prednimustine
Lomustine
Etoposide
Hodgkin Disease
Combination Drug Therapy
Therapeutics
Alopecia
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Elörehaladott stádiumú Hodgkin-kóros betegek kezelése CCNU, etoposide és prednimustine (CEP) terápiával. / Illés, A.; Bányai, A.; Szegedi, G.

In: Orvosi Hetilap, Vol. 135, No. 22, 29.05.1994, p. 1187-1190.

Research output: Contribution to journalArticle

@article{3a036bac0f4444eea7d477d093f6ba34,
title = "El{\"o}rehaladott st{\'a}dium{\'u} Hodgkin-k{\'o}ros betegek kezel{\'e}se CCNU, etoposide {\'e}s prednimustine (CEP) ter{\'a}pi{\'a}val.",
abstract = "The authors treated 21 advanced, pretreated Hodgkin's disease patients with CEP (CCNU, etoposide, prednimustine) polychemotherapy between March 1988 and February 1993. Complete remission was achieved in 4 patients, partial remission in 8 patients, while 9 patients were unresponsive to treatment. None of the complete responders relapsed during the follow-up period, and the median duration of remission was 24 months. The median survival for the unresponsive and partially responsive patients was less than half a year. Side-effects included gastrointestinal symptoms, myelosuppression and alopecia, but treatment-related deaths did not occur. The present data confirm the favourable impact of CEP polychemotherapy on pretreated, advanced Hodgkin's disease patients.",
author = "A. Ill{\'e}s and A. B{\'a}nyai and G. Szegedi",
year = "1994",
month = "5",
day = "29",
language = "Hungarian",
volume = "135",
pages = "1187--1190",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22",

}

TY - JOUR

T1 - Elörehaladott stádiumú Hodgkin-kóros betegek kezelése CCNU, etoposide és prednimustine (CEP) terápiával.

AU - Illés, A.

AU - Bányai, A.

AU - Szegedi, G.

PY - 1994/5/29

Y1 - 1994/5/29

N2 - The authors treated 21 advanced, pretreated Hodgkin's disease patients with CEP (CCNU, etoposide, prednimustine) polychemotherapy between March 1988 and February 1993. Complete remission was achieved in 4 patients, partial remission in 8 patients, while 9 patients were unresponsive to treatment. None of the complete responders relapsed during the follow-up period, and the median duration of remission was 24 months. The median survival for the unresponsive and partially responsive patients was less than half a year. Side-effects included gastrointestinal symptoms, myelosuppression and alopecia, but treatment-related deaths did not occur. The present data confirm the favourable impact of CEP polychemotherapy on pretreated, advanced Hodgkin's disease patients.

AB - The authors treated 21 advanced, pretreated Hodgkin's disease patients with CEP (CCNU, etoposide, prednimustine) polychemotherapy between March 1988 and February 1993. Complete remission was achieved in 4 patients, partial remission in 8 patients, while 9 patients were unresponsive to treatment. None of the complete responders relapsed during the follow-up period, and the median duration of remission was 24 months. The median survival for the unresponsive and partially responsive patients was less than half a year. Side-effects included gastrointestinal symptoms, myelosuppression and alopecia, but treatment-related deaths did not occur. The present data confirm the favourable impact of CEP polychemotherapy on pretreated, advanced Hodgkin's disease patients.

UR - http://www.scopus.com/inward/record.url?scp=0028782053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028782053&partnerID=8YFLogxK

M3 - Article

VL - 135

SP - 1187

EP - 1190

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22

ER -